AbbVie Targets Post Humira Growth With Cell Therapy And RINVOQ Expansion

AbbVie (NYSE:ABBV) has agreed to acquire Capstan Therapeutics to expand its work in in vivo CAR-T cell therapy. The company ...
Hosted on MSN

AbbVie Settles Rinvoq Patent Dispute: What It Means for the Stock

Shares of AbbVie ABBV rose over 4% to a record high on Thursday after the company announced that it had settled patent litigation with all generic manufacturers who had sought the FDA’s approval for ...
Fierce Pharma

AbbVie, hitting record sales on Skyrizi gains, holds its own in growing IBD arena despite J&J competition

Billions of dollars in U.S. biosimilar erosion to AbbVie’s blockbuster immunology drug Humira is no match for its rising ...
FiercePharma

AbbVie strengthens Rinvoq's case to treat alopecia, will send data to regulators

For the second time in the last three weeks, AbbVie has revealed successful results from a phase 3 study of Rinvoq as a treatment for the hair-loss disease alopecia areata (AA). The second replicate ...
Hosted on MSN

AbbVie's Rinvoq Gets EU Nod for 8th Indication Giant Cell Arteritis

AbbVie ABBV announced that the European Commission has granted marketing approval to its blockbuster drug Rinvoq for treating giant cell arteritis (“GCA”), an autoimmune disease that causes ...